Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ampyra Approval: Acorda's Lessons Learned

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

There are many factors that contributed to Acorda's success in gaining approval for Ampyra (dalfampridine), but looking back at the process, CEO Ron Cohen and Chief Scientific Officer Andy Blight agree that the biggest asset was having a Special Protocol Assessment for the Phase III trials.
Advertisement

Related Content

BIO 2015 Dispatches: Acorda CEO Cohen To Bring 'Passion' To BIO Chairmanship
Behind The Approval Letter: A Year Of Drug Review Profiles
Behind The Approval Letter: A Year Of Drug Review Profiles
PDUFA V: FDA Offers Mid-Cycle Review Talks, But Industry Wants Them Later
The Long Road To Approval: Acorda Experience With Ampyra Shows Success Of Novel Analysis Plan
Launching Ampyra: What Drug Companies Can Learn From The Experience
Launching Ampyra: What Drug Companies Can Learn From The Experience
FDA Says "Agreement" Does Not Have To Be Holy Grail Of SPA Discussions

Topics

Advertisement
UsernamePublicRestriction

Register

PS004606

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel